Research progress on the complement inhibitors in neuromyelitis optica spectrum disorders
10.3760/cma.j.cn113694-20240813-00550
- VernacularTitle:补体抑制剂治疗视神经脊髓炎谱系疾病的新进展
- Author:
Xiaona XU
1
;
Rui LIU
1
;
Chunsheng YANG
1
Author Information
1. 天津医科大学总医院神经内科，天津 300052
- Publication Type:Journal Article
- Keywords:
Neuromyelitis optica;
Autoimmune diseases;
Neuromyelitis optica spectrum disorders;
Complement system;
Complement inhibitors
- From:
Chinese Journal of Neurology
2025;58(4):444-448
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica spectrum disorders (NMOSD) refer to a group of autoimmune-mediated central nervous system inflammatory demyelinating diseases that primarily affect the optic nerve and spinal cord. Most patients have anti-aquaporin 4 (AQP4) autoantibodies. The activation of the complement system plays a crucial role in the pathogenesis of AQP4 IgG seropositive NMOSD. In recent years, complement inhibitors, such as eculizumab, have demonstrated promising efficacy and development prospects in AQP4 IgG seropositive NMOSD patients. This review article focuses on the advancements made in the utilization of complement inhibitors for the management of NMOSD.
